- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Genmab AS ADR (GMAB)
Genmab AS ADR stock price live, this page displays NASDAQ GMAB stock exchange data. View the GMAB premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Genmab AS ADR real time stock price chart below.
What Is the Genmab AS ADR Stock Price Today?
The Genmab AS ADR stock price today is 37.43.
What Is the Stock Symbol for Genmab AS ADR?
The stock ticker symbol for Genmab AS ADR is GMAB.
Is GMAB the Same as $GMAB?
$GMAB is a common way to refer to the Genmab AS ADR ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Genmab AS ADR Trade On?
Genmab AS ADR is listed and trades on the NASDAQ stock exchange.
Is Genmab AS ADR a Good Stock to Buy?
Determining whether Genmab AS ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Genmab AS ADR share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GMAB quote. (ISIN: US3723032062)
What Is the Genmab AS ADR Stock Price Today?
The Genmab AS ADR stock price today is 37.43.
What Is the Stock Symbol for Genmab AS ADR?
The stock ticker symbol for Genmab AS ADR is GMAB.
Is GMAB the Same as $GMAB?
$GMAB is a common way to refer to the Genmab AS ADR ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Genmab AS ADR Trade On?
Genmab AS ADR is listed and trades on the NASDAQ stock exchange.
Is Genmab AS ADR a Good Stock to Buy?
Determining whether Genmab AS ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Genmab AS ADR share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GMAB quote. (ISIN: US3723032062)
37.43
-0.37(-0.98%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
36.97
37.62
52 wk Range
23.62
40.17
GMAB is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
36.9737.62
52 wk Range
23.6240.17
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
GMAB Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
42.76
Upside
+14.25%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in overbought territory
Genmab AS receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Genmab AS receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Genmab AS receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Genmab AS receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy
Analyst Ratings
11 Buy
1 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 42.76
(+14.25% Upside)
Genmab AS ADR SWOT Analysis
Market Valuation | Analysts suggest a potential undervaluation, with price targets ranging from $47 to DKK 2,400, highlighting the market's complex view of Genmab's prospects |
Pipeline Potential | Explore Genmab's diverse pipeline, including promising candidates like Epkinly, GEN3014, and Rina S., poised to shape the company's future growth |
Financial Crossroads | Despite strong financials and a 96.1% gross profit margin, Genmab's stock faces challenges as it prepares for the post-Darzalex era |
Antibody Innovato | Genmab, a Danish biotech leader, leverages proprietary technology to develop cancer-fighting antibodies, boasting eight approved medicines and a robust pipeline |
Genmab AS ADR Earnings Call Summary for Q2/2026
- Genmab raised FY 2026 revenue guidance to DKK 4.3-4.5B, up 19% YoY at midpoint; operating profit guidance lifted 7% to DKK 1.1-1.4B.
- H1 revenue rose 25% YoY driven by EPKINLY (up 48% YoY) and DARZALEX; proprietary portfolio sales jumped 37% to DKK 396M.
- Shares fell 1.88% to $28.71 despite raised guidance, as investors await key late-stage data readouts for EPKINLY, petosemtamab in Q4 2026-Q1 2027.
- Operating profit increased 18% in H1 while OpEx guidance rose only 2%, reflecting disciplined spending despite investments in phase III trials and launches.
- Management highlighted commercial momentum with EPKINLY expanding into community settings and 90%+ of key customers ordering for multiple sites.
Last Updated: 08/06/2026, 01:43 PM
Read Full TranscriptGenmab AS ADR investor slides for Q2/2026
Last Update: Aug 06, 2026
See full investor slides
Earnings
Latest Release
Aug 06, 2026
EPS / Forecast
0.49 / 0.34
Revenue / Forecast
1.16B / 1.1B
Compare GMAB to Peers and Sector
Metrics to compare | GMAB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGMABPeersSector | |
|---|---|---|---|---|
P/E Ratio | 28.2x | 20.1x | −0.3x | |
PEG Ratio | −0.74 | −0.21 | 0.00 | |
Price / Book | 3.7x | 5.0x | 2.6x | |
Price / LTM Sales | 5.4x | 4.4x | 3.0x | |
Upside (Analyst Target) | 10.5% | 5.3% | 58.2% | |
Fair Value Upside | Unlock | 9.1% | 7.5% | Unlock |
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter’s syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Genmab AS ADR (GMAB) Stock Price Today?
The Genmab AS ADR stock price today is 37.43 USD.
What Stock Exchange Does Genmab AS ADR Trade On?
Genmab AS ADR is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Genmab AS ADR?
The stock symbol for Genmab AS ADR is "GMAB."
What Is the Genmab AS ADR Market Cap?
As of today, Genmab AS ADR market cap is 22.20B USD.
What Is Genmab AS ADR's Earnings Per Share (TTM)?
The Genmab AS ADR EPS (TTM) is 12.65.
When Is the Next Genmab AS ADR Earnings Date?
Genmab AS ADR will release its next earnings report on Nov 05, 2026.
From a Technical Analysis Perspective, Is GMAB a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Genmab AS ADR Stock Split?
Genmab AS ADR has split 1 times.
How Many Employees Does Genmab AS ADR Have?
Genmab AS ADR has 3119 employees.
What is the current trading status of Genmab AS ADR (GMAB)?
As of Oct 07, 2026, Genmab AS ADR (GMAB) is trading at a price of 37.43 USD, with a previous close of 37.80 USD. The stock has fluctuated within a day range of 36.97 USD to 37.62 USD, while its 52-week range spans from 23.62 USD to 40.17 USD.
What Is Genmab AS ADR (GMAB) Price Target According to Analysts?
The average 12-month price target for Genmab AS ADR is 42.76 USD, with a high estimate of 58 USD and a low estimate of 33.5 USD. 11 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +14.25% Upside potential.
What Is the GMAB Premarket Price?
GMAB's last pre-market stock price is 37.19 USD. The pre-market share volume is 42,210.00, and the stock has decreased by -0.61, or -1.61%.
What Is the GMAB After Hours Price?
GMAB's last after hours stock price is 37.35 USD, the stock has decreased by -0.45, or -1.19%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.